← All trials
NCT07237425
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 14, 2025
- Primary completion
- Nov 14, 2026
- Completion date
- Jan 14, 2027
- First posted
- Nov 19, 2025
- Last posted
- Nov 19, 2025
- Enrollment
- 56
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Glonova Pharma Co., LtdLead sponsor
- Cathay General HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.